These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14714898)

  • 1. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
    Butters TD; Dwek RA; Platt FM
    Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic applications of imino sugars in lysosomal storage disorders.
    Butters TD; Dwek RA; Platt FM
    Curr Top Med Chem; 2003; 3(5):561-74. PubMed ID: 12570866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
    Lachmann RH
    Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate reduction therapy for glycosphingolipid storage disorders.
    Lachmann RH; Platt FM
    Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
    Butters TD; Mellor HR; Narita K; Dwek RA; Platt FM
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):927-45. PubMed ID: 12803927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate reduction therapy.
    Platt FM; Jeyakumar M
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement.
    Pastores GM
    Recent Pat CNS Drug Discov; 2006 Jan; 1(1):77-82. PubMed ID: 18221193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
    Boomkamp SD; Rountree JS; Neville DC; Dwek RA; Fleet GW; Butters TD
    Glycoconj J; 2010 Apr; 27(3):297-308. PubMed ID: 20186478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
    Elliot-Smith E; Speak AO; Lloyd-Evans E; Smith DA; van der Spoel AC; Jeyakumar M; Butters TD; Dwek RA; d'Azzo A; Platt FM
    Mol Genet Metab; 2008 Jun; 94(2):204-11. PubMed ID: 18387328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
    Andersson U; Butters TD; Dwek RA; Platt FM
    Biochem Pharmacol; 2000 Apr; 59(7):821-9. PubMed ID: 10718340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
    Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
    J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate reduction therapy for lysosomal storage diseases.
    Cox TM
    Acta Paediatr Suppl; 2005 Mar; 94(447):69-75; discussion 57. PubMed ID: 15895716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
    Andersson U; Reinkensmeier G; Butters TD; Dwek RA; Platt FM
    Biochem Pharmacol; 2004 Feb; 67(4):697-705. PubMed ID: 14757169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases.
    Tifft CJ; Proia RL
    Glycobiology; 2000 Dec; 10(12):1249-58. PubMed ID: 11159916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
    Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
    Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis.
    Mellor HR; Neville DC; Harvey DJ; Platt FM; Dwek RA; Butters TD
    Biochem J; 2004 Aug; 381(Pt 3):861-6. PubMed ID: 15128268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
    Jeyakumar M; Butters TD; Dwek RA; Platt FM
    Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
    Platt FM; Neises GR; Dwek RA; Butters TD
    J Biol Chem; 1994 Mar; 269(11):8362-5. PubMed ID: 8132559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.